| abstract |
Novel heterocyclic fused systems are disclosed herein which possess numerous biological activities, including but not limited to antibacterial activity, and usefulness to the treatment of many disease states, such as pathogenic infections. In particular, new imidazoles are disclosed along with related processes of preparation and methods of use as antibacterial agents. The disclosed compounds were found to be active against several Gram-positive bacteria, including Enterococcus faecalis and Bacillus subtilis , and were also found to be active against several species of multi-drug resistant Staphylococcus , such as S. aureus, S. saprophyticus, S. haemolyticus , and S. epidermidis. |